
FDA NEWS • TESTOSTERONE THERAPY
If you have considered testosterone replacement therapy but have questions about prostate health or age-related low testosterone, a June 2026 FDA announcement deserves attention.
On June 18, the U.S. Department of Health and Human Services announced that the FDA was requesting changes to testosterone prescribing information involving age-related hypogonadism, prostate cancer, and benign prostatic hyperplasia, commonly called BPH.
The key distinction
The announcement concerns requested labeling revisions. It should not be interpreted as confirmation that every testosterone product’s label has changed or that treatment is appropriate for every man. Your clinician should review the current prescribing information for the specific medication being considered. FDA testosterone information.
What changes did the FDA request?
Age-related hypogonadism
Remove the limitation stating that safety and effectiveness have not been established for this population.
Prostate cancer
Narrow the prostate-cancer contraindication to metastatic prostate cancer. This describes the requested prostate-related revision; it does not eliminate other contraindications or individual clinical considerations.
Enlarged prostate
Revise warnings to reflect findings in men with mild-to-moderate BPH, with continued monitoring emphasized for severe symptomatic disease.
HHS noted that available evidence generally has not shown increased prostate-cancer risk with TRT, while acknowledging that limited follow-up leaves important long-term uncertainties. The requested revisions retain prostate-risk assessment, screening before treatment, and monitoring during therapy. Read the June 18 HHS announcement.
Does this mean testosterone therapy cannot cause prostate cancer?
No. Reassuring research is different from proof of zero risk.
A prostate-safety analysis from the TRAVERSE trial found low rates of prostate cancer and no statistically significant difference between testosterone and placebo groups during the study. However, participants were carefully screened. Men with a history of prostate cancer, certain elevated PSA results, or severe urinary symptoms were excluded.
Those findings help inform care for men resembling the study population. They do not establish safety for every patient, particularly men with existing cancer or concerning prostate findings. Read the prostate-safety study.
For a broader explanation, see our guide: Does Testosterone Therapy Cause Prostate Cancer?
What if I have a history of prostate cancer?
A requested change to a contraindication does not automatically make someone a candidate for TRT.
If you have active prostate cancer, previous prostate-cancer treatment, or an abnormal PSA result, discuss hormone treatment with the clinicians managing your prostate care. The diagnosis, treatment history, PSA trend, symptoms, and current medication labeling all matter.
Professional guidance and prescribing information also serve different purposes. For example, the Endocrine Society’s published 2018 guideline recommends against starting testosterone in men with prostate cancer. A new regulatory announcement should not be treated as though every clinical guideline has simultaneously changed. Endocrine Society guidance.
Does every older man with low testosterone need treatment?
No. Age alone does not establish a need for TRT.
An appropriate evaluation considers symptoms, consistently low testosterone measurements, and possible causes. The Endocrine Society recommends confirming low testosterone with repeat morning fasting testing and investigating the underlying cause.
The decision also considers fertility goals and conditions that could make treatment unsuitable. A request to remove a labeling limitation does not replace that diagnostic process. Diagnosis and treatment guidance.
How is this different from the 2025 FDA update?
The February 2025 FDA action addressed cardiovascular labeling. Following its review of TRAVERSE, the agency requested removal of boxed-warning language about increased adverse cardiovascular outcomes.
That action also required warnings about increased blood pressure, based on blood-pressure monitoring studies. It did not mean testosterone treatment was free of cardiovascular concerns.
The June 2026 announcement addresses a different set of issues: age-related hypogonadism and prostate-related prescribing information. FDA’s February 2025 announcement.
What should patients do now?
Use the announcement as a starting point for a more informed conversation with your clinician.
- Do my symptoms and laboratory results support a diagnosis of testosterone deficiency?
- What does the current label for my proposed medication say?
- Does my prostate history require evaluation by a urologist?
- What baseline testing and follow-up would be appropriate?
- How could treatment affect my blood pressure or fertility goals?
If you already receive TRT, discuss questions with your prescriber before changing treatment.
Discuss testosterone therapy with NovaGenix
NovaGenix provides physician-led testosterone evaluation and care in Jupiter, Florida. A consultation can help you understand how your symptoms, laboratory findings, medical history, and treatment goals fit together.
Learn about testosterone replacement therapy at NovaGenix and Dr. Timothy Mackey.
609 N Hepburn Ave Ste 106, Jupiter, FL 33458
Evaluation does not guarantee a prescription. Treatment decisions are individualized.
This article provides general education and does not replace medical advice. Regulatory announcements, product labeling, and clinical recommendations can change. Decisions should use current prescribing information and an individualized medical assessment. Ratings may change; follow the linked profiles for current details.


.png)